Literature DB >> 9241547

Effect of the alpha-1 adrenoceptor blocker on tissue norepinephrine contents in human benign prostatic hyperplasia.

M Ishigooka1, S Hayami, T Hashimoto, Y Suzuki, O Ichiyanagi, T Nakada.   

Abstract

To see the effect of the alpha-adrenergic blocking agent on tissue norepinephrine contents of the prostate, norepinephrine (NE) levels were investigated in patients with symptomatic benign prostatic hyperplasia (BPH). Morphometrical analyses were also performed to detect the differences in tissue composition. Nineteen patients were subdivided into two groups. Patients in Group 1 were given tamsulosin hydrochloride (0.2 mg/day) for at least 4 weeks before transurethral resection of the prostate (TURP), while patients in the control group (Group 2) underwent no previous treatment for BPH before TURP. Tissue NE contents were investigated by high performance liquid chromatography on a chip of the prostate obtained by TURP. These two groups were closely similar in age distribution, prostatic size, results of preoperative symptom scoring and relative proportion of smooth muscle component within the evaluated specimen. In the present series, tissue NE contents in these groups were not statistically different (p = 0.64). Chronic and acute administration of the alpha-1 antagonist did not apparently influence the tissue NE level in patients with BPH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241547     DOI: 10.1007/bf02551341

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.

Authors:  M Caine
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

3.  Catecholamine metabolism in pheochromocytoma and normal adrenal medullae.

Authors:  T Nakada; H Furuta; T Katayama
Journal:  J Urol       Date:  1988-12       Impact factor: 7.450

4.  Prazosin in the treatment of prostatic obstruction. A placebo-controlled study.

Authors:  R S Kirby; S W Coppinger; M O Corcoran; C R Chapple; M Flannigan; E J Milroy
Journal:  Br J Urol       Date:  1987-08

Review 5.  Nonoperative management of benign prostatic hyperplasia.

Authors:  H Lepor
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

6.  Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia.

Authors:  G Bartsch; H R Müller; M Oberholzer; H P Rohr
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

7.  Reduction in norepinephrine content of sympathetic neuroeffector organs by alpha adrenergic antagonists and nerve stimulation: evidence for presynaptic control of sympathetic transmitter release in intact animal.

Authors:  A R Wakade; T D Wakade
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

8.  The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.

Authors:  H Lepor; R Tang; E Shapiro
Journal:  Prostate       Date:  1993       Impact factor: 4.104

9.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

Authors:  H Lepor; S Auerbach; A Puras-Baez; P Narayan; M Soloway; F Lowe; T Moon; G Leifer; P Madsen
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

10.  Effects of prazosin in patients with benign prostatic obstruction.

Authors:  H Hedlund; K E Andersson; A Ek
Journal:  J Urol       Date:  1983-08       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.